Elsunersen (PRAX-222) is an investigational antisense oligonucleotide therapy in development for early-seizure-onset SCN2A developmental and epileptic encephalopathy. It is designed to reduce SCN2A expression in gain-of-function disease and has shown positive Phase 1/2 results with progression into pivotal EMBRAVE3 development. The therapy remains unapproved.
Multiple analysts have raised price targets on Praxis Precision Medicines, with Wolfe Research initiating coverage at $500 and Guggenheim increasing its target to $800, citing strong market potential for ulixacaltamide in essential tremor.
Praxis Precision Medicines submitted NDAs for ulixacaltamide and relutrigine to the FDA, reported cash and investments of $926 million as of December 31, 2025, and disclosed a net loss of $303.3 million for full-year 2025.
